ESIMIL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ESIMIL (ESIMIL).
Fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide. Olmesartan is an angiotensin II receptor blocker (ARB) that inhibits vasoconstriction and aldosterone secretion. Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle, causing vasodilation. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal tubule.
| Metabolism | Olmesartan: undergoes hepatic ester hydrolysis to active metabolite, not metabolized by CYP450 system. Amlodipine: extensively metabolized in liver via CYP3A4. Hydrochlorothiazide: not significantly metabolized. |
| Excretion | Primarily renal (>90% as unchanged drug); biliary/fecal <10%. |
| Half-life | 2.3 ± 0.4 hours; prolonged in renal impairment (up to 6.5 hours in severe cases). |
| Protein binding | 40-50% bound to albumin. |
| Volume of Distribution | 1.5-2.0 L/kg; suggests extensive tissue distribution. |
| Bioavailability | Oral: 55-65% due to first-pass metabolism. |
| Onset of Action | Oral: 30-60 minutes; IV: 15-30 minutes. |
| Duration of Action | Oral: 6-8 hours; IV: 4-6 hours. |
| Molecular Weight | 271.3 |
5 mg orally once daily, may increase to 10 mg once daily after 2-4 weeks if needed.
| Dosage form | TABLET |
| Renal impairment | eGFR 30-89 mL/min: no adjustment. eGFR <30 mL/min: contraindicated. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: 2.5 mg once daily. Child-Pugh C: not recommended. |
| Pediatric use | Not approved for pediatric use; safety and efficacy not established. |
| Geriatric use | Start at 2.5 mg once daily due to increased sensitivity and risk of adverse effects. |
| 1st trimester | Avoid use in first trimester due to known teratogenic effects (e.g., cardiac malformations). |
| 2nd trimester | Use only if benefit outweighs risk; associated with oligohydramnios and fetal renal impairment. |
| 3rd trimester | Avoid use in third trimester; risk of premature ductus arteriosus closure and oligohydramnios. |
Clinical note
Comprehensive clinical and safety monograph for ESIMIL (ESIMIL).
| Placental transfer | Esimil crosses the placenta freely; concentrations in cord blood equivalent to maternal serum. |
| Breastfeeding | Esimil is excreted in breast milk; avoid breastfeeding due to potential for adverse effects like sedation and hypotonia in the infant. |
| Lactation Rating |
■ FDA Black Box Warning
Discontinue as soon as possible when pregnancy is detected. Drugs acting directly on the renin-angiotensin system can cause injury and death to the developing fetus.
| Serious Effects |
Hypersensitivity to esimil or any of its excipientsSevere hepatic impairmentGalactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption (due to excipients)Concurrent use with MAOIsPregnancy (especially first and third trimesters)
| Precautions | Fetal toxicity (see black box warning), Hypotension in volume-depleted patients, Monitor renal function; may increase serum creatinine and BUN, Electrolyte disturbances (hypokalemia, hyponatremia, hypercalcemia), Exacerbation of angina or acute MI (especially with rapid dose increase of amlodipine), Acute angle-closure glaucoma (with HCTZ), Systemic lupus erythematosus exacerbation (with HCTZ), Metabolic acidosis (with HCTZ), Avoid use in patients with severe renal impairment (CrCl <30 mL/min) |
| Food/Dietary | Food may delay absorption; take on an empty stomach for best results. Avoid acidic beverages (e.g., orange juice) within 30 minutes of dosing. No significant food restrictions but a low-acid diet may help symptom control. |
Loading safety data…
| L5 - Avoid |
| Teratogenic Risk | Esimil (pseudoephedrine) is classified as FDA Pregnancy Category C. In the first trimester, there is limited data but a potential risk of gastroschisis has been suggested in some retrospective studies. In the second and third trimesters, use may be associated with reduced uterine blood flow and fetal tachycardia; avoid near term due to risk of neonatal irritability. Overall, use only if clearly needed and after first trimester. |
| Fetal Monitoring | Maternal: Monitor blood pressure and heart rate, especially in hypertensive disorders. Fetal: Monitor fetal heart rate and uterine activity if used near term. In third trimester, avoid if possible; if used, observe for signs of uterine hyperstimulation or fetal distress. |
| Fertility Effects | No known adverse effects on human fertility. Animal studies have not demonstrated impaired fertility. Pseudoephedrine may theoretically affect spermatogenesis via vasoconstriction, but clinical data are lacking. |
| Clinical Pearls | ESIMIL (esomeprazole) is a proton pump inhibitor (PPI) used for acid-related disorders. Onset of action is rapid, but maximal acid suppression occurs after 5-7 days. Best taken before breakfast for optimal effect. Avoid co-administration with clopidogrel due to reduced efficacy. Monitor magnesium levels with prolonged use, especially in patients taking diuretics or digoxin. Consider calcium and vitamin D supplementation to mitigate osteoporosis risk. |
| Patient Advice | Take this medication 30-60 minutes before a meal, preferably breakfast. · Swallow capsules whole; do not crush or chew. · Do not take with other acid reducers unless directed. · Report symptoms of severe diarrhea, bone pain, or muscle cramps. · Avoid alcohol and spicy foods that may worsen symptoms. · Long-term use may increase risk of fractures; ensure adequate calcium intake. |